研究报告

PIK3CA框内缺失突变激活PI3K/AKT信号导致巨指(趾)畸形

展开
  • 首都医科大学附属北京积水潭医院手外科北京 100035
武竞衡,博士,副主任医师。研究方向:手外科。E-mail: wujingheng1@gmail.com

收稿日期: 2026-01-29

  修回日期: 2026-04-25

  网络出版日期: 2026-05-07

基金资助

北京市自然科学基金项目(7222089)

PIK3CA in-frame deletion-activated PI3K/AKT signaling pathway drives macrodactyly

Expand
  • Department of Hand Surgery, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100035, China

Received date: 2026-01-29

  Revised date: 2026-04-25

  Online published: 2026-05-07

Supported by

Beijing Natural Science Foundation(7222089)

摘要

巨指(趾)畸形是一种以单/多指(趾)局限性过度生长为核心特征的先天性肢体发育异常,常伴有骨骼、软组织及神经组织的病理改变,大多数属于体细胞变异。既往研究已证实,PIK3CA基因致病性变异是该疾病发生的关键遗传基础,但具体致病机制尚不清楚。本研究共纳入13例临床诊断为单纯性巨指(趾)畸形的患者,经全外显子测序分析技术结合Sanger测序,发现其中1例患者携带PIK3CA基因嵌合新发框内缺失突变(c.307_312del/p.Glu103_Pro104del)(其父母均未携带该变异)。根据美国医学遗传学与基因组学学会的遗传变异分类标准与指南,该变异被判定为意义未明变异(PM4+PM2_Supporting+PM6_Supporting)。蛋白结构预测分析表明,该框内缺失突变改变了蛋白局部构象和表面静电势。进一步通过构建野生型和突变型表达载体,以致病性明确的c.353G>A/p.Gly118Asp突变作对照,转染HEK293T细胞,对该突变进行了功能分析。结果表明,虽然该突变对PIK3CA基因mRNA和蛋白表达水平较野生型无明显变化,但是却促进了其下游AKT蛋白第308位(Thr308)与第473位(Ser473)磷酸化。这提示,该突变可能通过激活PI3K/AKT信号通路,进而导致患者局部组织过度生长的表型。本研究不仅拓展了巨指(趾)畸形的遗传变异谱,也为进一步阐明PI3K/AKT通路在PIK3CA相关过度生长谱系中的作用提供了实验依据。

本文引用格式

武竞衡, 陈山林, 薛云皓, 栗鹏程, 田萌萌 . PIK3CA框内缺失突变激活PI3K/AKT信号导致巨指(趾)畸形[J]. 遗传, 2026 , 48(8) : 796 -806 . DOI: 10.16288/j.yczz.25-340

Abstract

Macrodactyly is a congenital abnormality characterized by overgrowth of single or multiple digits, frequently accompanied by pathological changes in bone, soft tissue, and nerve tissue, and is caused mostly by somatic variants. Previous studies have demonstrated that macrodactyly is predominantly caused by pathogenic variants in the PIK3CA gene, yet the underlying molecular mechanism remains unclear. In this study, we analyzed 13 patients clinically diagnosed with isolated macrodactyly. Through whole-exome and Sanger sequencing, we identified one pediatric patient carrying a novel mosaic de novo in-frame deletion mutation (c.307_312del/p.Glu103_Pro104del) in the PIK3CA gene, which was not detected in either parent. According to the American College of Medical Genetics and Genomics (ACMG) guidelines, we classified this mutation as a variant of uncertain significance (PM4+PM2_Supporting+PM6_Supporting). Protein structure prediction analysis indicated that this in-frame deletion altered the protein’s local conformation and surface electrostatic potential. Furthermore, the wild-type and mutant expression vectors were constructed, including the well-established pathogenic mutation c.353G>A/p.Gly118Asp in PIK3CA gene as a control. We transfected these vectors into HEK293T cells for functional analyses, respectively. The results showed that although this mutation did not significantly affect PIK3CA mRNA or protein expression levels, it promoted the phosphorylation of downstream AKT protein at both Thr308 and Ser473. Therefore, the mutation may express the localized overgrowth phenotype by activating the PI3K/AKT signaling pathway. This study not only expands the genetic variant spectrum of macrodactyly, but also further clarifies the role of the PI3K/AKT pathway in the PIK3CA-related overgrowth.

参考文献

[1] Shen XF, Gasteratos K, Spyropoulou GA, Yin F, Rui YJ. Congenital difference of the hand and foot: pediatric macrodactyly. J Plast Reconstr Aesthet Surg, 2022, 75(11): 4054-4062.
[2] Orloff MS, He X, Peterson C, Chen FS, Chen JL, Mester JL, Eng C. Germline PIK3CA and AKT1 mutations in cowden and cowden-like syndromes. Am J Hum Genet, 2013, 92(1): 76-80.
[3] Giżewska-Kacprzak K, Śliwiński M, Nicieja K, Babiak- Choroszczak L, Walaszek I. Macrodactyly. Children (Basel), 2024, 11(7): 753.
[4] Hardwicke J, Khan MAA, Richards H, Warner RM, Lester R. Macrodactyly - options and outcomes. J Hand Surg Eur Vol, 2013, 38(3): 297-303.
[5] Liu Y, Yang ZY, Pang CJ, Fan XB, Zhao CY, Wei ZK. A visual analysis of research hotspots and trends on macrodactyly between 2005 and 2024. Orphanet J Rare Dis, 2005, 20(1): 489.
[6] Aytenfisu TY, Campbell HM, Chakrabarti M, Amzel LM, Gabelli SB. Class I PI3K biology. Curr Top Microbiol Immunol, 2022, 436: 3-49.
[7] Vadas O, Burke JE, Zhang XX, Berndt A, Williams RL. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal, 2011, 4(195): re2.
[8] Hennessy BT, Smith DL, Ram PT, Lu YL, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov, 2005, 4(12): 988-1004.
[9] Tang XW, Chu D, Yan SN, Yin YF, Bian Q, Weng B, Chen B, Ran ML. MiR-191 promotes the porcine immature Sertoli cell proliferation by targeting the BDNF gene through activating the PI3K/AKT signaling pathway. Hereditas(Beijing), 2021, 43(7): 680-693.
  唐湘薇, 楚丹, 颜赛娜, 尹艳飞, 卞桥, 翁波, 陈斌, 冉茂良. MiR-191靶向BDNF基因通过激活PI3K/AKT信号通路促进猪未成熟支持细胞增殖. 遗传, 2021, 43(7): 680-693.
[10] Fruman DA, Chiu HY, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell, 2017, 170(4): 605-635.
[11] Lindhurst MJ, Parker VER, Payne F, Sapp JC, Rudge S, Harris J, Witkowski AM, Zhang QF, Groeneveld MP, Scott CE, Daly A, Huson SM, Tosi LL, Cunningham ML, Darling TN, Geer J, Gucev Z, Sutton VR, Tziotzios C, Dixon AK, Helliwell T, O'Rahilly S, Savage DB, Wakelam MJO, Barroso I, Biesecker LG, Semple RK. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet, 2012, 44(8): 928-933.
[12] Iriarte Fuster A, Cerdà Serra P, Riera-Mestre A. PIK3CA- related overgrowth spectrum (PROS): new insight in known diseases. Med Clin (Barc), 2021, 157(10): 483-488.
[13] Vahidnezhad H, Youssefian L, Baghdadi T, Sotoudeh S, Tavassoli A, Zeinali S, Afsharaalam S, Uitto J. Phenotypic heterogeneity in PIK3CA-related overgrowth spectrum. Br J Dermatol, 2016, 175(4): 810-814.
[14] Tian W, Huang YZ, Sun LY, Guo Y, Zhao S, Lin M, Dong XY, Zhong WY, Yin YH, Chen ZF, Zhang N, Zhang YQ, Wang LL, Lin JC, Yan ZH, Yang XZ, Zhao JH, Qiu GX, Zhang JG, Wu ZH, Wu N, (Deciphering Disorders Involving Scoliosis, Comorbidities) study group. Phenotypic and genetic spectrum of isolated macrodactyly:somatic mosaicism of PIK3CA and AKT 1 oncogenic variants. Orphanet J Rare Dis, 2020, 15(1): 288.
[15] Wu JH, Tian W, Tian GL, Tian MM, Chen SL, Tian W. PIK3CA mutation analysis in isolated macrodactyly. Chin J Surg, 2018, 56(7): 538-542.
  武竞衡, 田伟, 田光磊, 田萌萌, 陈山林, 田文. 单纯性巨指(趾)症PIK3CA基因突变位点研究. 中华外科杂志, 2018, 56(7): 538-542.
[16] Tripolszki K, Knox R, Parker V, Semple R, Farkas K, Sulák A, Horváth E, Széll M, Nagy N. Somatic mosaicism of the PIK3CA gene identified in a Hungarian girl with macrodactyly and syndactyly. Eur J Med Genet, 2016, 59(4): 223-226.
[17] National Cancer Institute. Macrodactyly (NCI Thesaurus Code C48900)[EB/OL]. ( 2020-02-07). https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48900.
[18] Wu JH, Tian GL, Tian MM, Chen SL. Clinical characteristics of 170 cases of macrodactyly. J Peking Univ (Health Sciences), 2021, 53(3): 590-593.
  武竞衡, 田光磊, 田萌萌, 陈山林. 170例巨指(趾)患者临床特点分析. 北京大学学报(医学版), 2021, 53(3): 590-593.
[19] Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB, Amzel LM. The structure of a human p110alpha/ p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science, 2007, 318(5857): 1744-1748.
[20] Mora A, Komander D, van Aalten DMF, Alessi DR. PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol, 2004, 15(2): 161-170.
[21] Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor- mTOR complex. Science, 2005, 307(5712): 1098-1101.
[22] Wu XY, Renuse S, Sahasrabuddhe NA, Zahari MS, Chaerkady R, Kim MS, Nirujogi RS, Mohseni M, Kumar P, Raju R, Zhong J, Yang J, Neiswinger J, Jeong JS, Newman R, Powers MA, Somani BL, Gabrielson E, Sukumar S, Stearns V, Qian J, Zhu H, Vogelstein B, Park BH, Pandey A. Activation of diverse signalling pathways by oncogenic PIK3CA mutations. Nat Commun, 2014, 5: 4961.
[23] Yan W, Zhang B, Wang HJ, Mo R, Jiang XY, Qin W, Ma L, Lin ZM. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway. Hereditas, 2021, 158(1): 18.
[24] Burke JE, Williams RL. Synergy in activating class I PI3Ks. Trends Biochem Sci, 2015, 40(2): 88-100.
[25] Burke JE, Perisic O, Masson GR, Vadas O, Williams RL. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc Natl Acad Sci USA, 2012, 109(38): 15259-15264.
[26] Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny D, Wolfson HJ, Backer JM, Williams RL. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science, 2007, 317(5835): 239-242.
[27] Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer- specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA, 2007, 104(13): 5569-5574.
[28] Berndt A, Miller S, Williams O, Le DD, Houseman BT, Pacold JI, Gorrec F, Hon WC, Liu Y, Rommel C, Gaillard P, Rückle T, Schwarz MK, Shokat KM, Shaw JP, Williams RL. The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol, 2010, 6(2): 117-124.
[29] McCarthy N. Structural survey. Nat Rev Cancer, 2008, 8: 76-77.
[30] Blesinger H, Kaulfuß S, Aung T, Schwoch S, Prantl L, Rößler J, Wilting J, Becker J. PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations. PLoS One, 2018, 13(7): e0200343.
文章导航

/